ARK Fintech Innovation ETF vs Johnson & Johnson — how do they compare? ARK Fintech Innovation ETF trades at $42.7, while Johnson & Johnson trades at $260.76 (market cap $626.09B). The key difference: Johnson & Johnson pays a 2.06% dividend while ARK Fintech Innovation ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, ARK Fintech Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ARKF | JNJ | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $58.82 | $267.24 |
52-Week Low | $36.14 | $172.78 |
Market Cap | — | $626.09B |
Volume | — | 6,156,228 |
Enterprise Value | — | $654.37B |
Dividend Yield | — | 2.06% |
Signals from Pluang's Aura AI — not financial advice
ARKF trades at $42.70, down 0.93% today amid a broader fintech and crypto sector consolidation. The ETF's technical outlook is bullish based on moving averages, but oscillators are neutral with an overbought short-term RSI. Recent underperformance includes a 23% decline since July 2025, lagging the S&P 500 by 45 percentage points, with elevated volatility at 33.6%.
Outlook remains cautious due to high valuation multiples and sector headwinds. Risks include stretched P/E of 33x and PEG of 2.0x, signaling potential overvaluation. Investor sentiment is mixed, with a Hold rating reflecting fair valuation concerns amid ongoing consolidation pressures.
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
Trailing returns across standard periods
Latest headlines on both assets
ARKF is an actively managed ETF that invests in companies leading the way in fintech innovation. Key themes include mobile payments, digital wallets, blockchain technology, and frictionless funding platforms.
Read more on ARKF →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →